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Abstract
Magnetic #uid hyperthermia (MFH) selectively heats up tissue by coupling alternating current (AC) magnetic "elds to
targeted magnetic #uids, so that boundaries of di!erent conductive tissues do not interfere with power absorption. In this
paper, a new AC magnetic "eld therapy system for clinical application of MFH is described. With optimized magnetic
nanoparticle preparations it will be used for target-speci"c glioblastoma and prostate carcinoma therapy.
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1. Introduction and state-of-the-art
Hyperthermia intensi"es the e$cacy of radiation
and/or chemotherapy. Due to technical and phys-
ical limitations, some regions of the body cannot be
heated adequately with currently available hyper-
thermia systems or are only accessible by traumatic
and highly invasive interstitial methods, e.g., like
with brain tumors and locally advanced prostate
carcinomas.
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There has been much interest in using ther-
moradiotherapy in the treatment of primary brain
tumors because patients treated conventionally
have a very poor prognosis despite a large variety
of therapeutic strategies and concepts [1]. The ex-
tent of resection is an important prognostic factor
for survival [2]. Poorly circumscribed are malig-
nant brain tumors, e.g., anaplastic astrocytomas or
glioblastomas. Recurrent tumor growth, i.e., loss of
local control at the primary site is the main cause of
therapeutic failures even after aggressive treat-
ments like interstitial brain implant boost [3].
Many years ago, it was shown that hyperthermia
greatly enhances cytotoxicity of radiation and drug
treatment with brain tumor cell lines, which were
also con"rmed by multimodal hyperthermia stud-
ies with rats, rabbits and dogs [4]. Toxicity studies
revealed a maximum tolerable thermal dose of nor-
mal brain in dogs to be 443C, 30min, using inter-
stitial microwave antennas. Known side e!ects of
hyperthermia in animal experiments are cerebral
necrosis, edema, focal hemorrhage and infarction.
A breakdown of the blood}brain barrier is ob-
served at temperatures of 42.53C}433C, 60min. Cli-
nical studies performed so far have shown that
interstitial brain hyperthermia is feasible and
that toxicity is acceptable under careful control of
the heating and limitation of the target volume.
In a recently published randomized phase II/III
study, 112 patients with glioblastoma multiformae
(GM) received a combination of brachytherapy
boost$interstitial hyperthermia [5]. The results
of this important study clearly demonstrate that
adjuvant interstitial brain hyperthermia given be-
fore and after brachytherapy boost, after conven-
tional radiotherapy, signi"cantly improved GM
patient survival (2 year survival 31% versus 15%)
with acceptable toxicity. Heating was performed
with interstitial microwave antennas (950MHz),
which were implanted 1.2}1.8 cm apart within the
tumor. The power was manually controlled, so that
the tumor temperature did not exceed 503C and
443C in the normal brain tissue. Toxicities were
more frequent in the hyperthermia arm combined
with mild neurological changes and seizures (last-
ing)5min), which were most probably caused by
the overheating of normal brain tissue. Neither
problems with edema and intracranial pressure nor
infarction or thrombosis was reported in this study.
Our own results with the same method using
microwave antennas operating at 434MHz sup-
port these encouraging "ndings [6}9]. In con-
clusion, the present preclinical and clinical data
show that hyperthermia is feasible and e!ective in
combination with radiation therapy. However, in
the clinical situation, temperature homogeneity is
still the major limiting factor for the therapeutic
outcome, which largely requires improvements of
intracranial hyperthermia application methods.
Interstitial hyperthermia also has a potential in
the treatment of locally advanced prostate carci-
nomas as an adjunct to interstitial and conformal
external beam radiation therapy [10]. The utiliz-
ation of interstitial radioactive seeds yields signi"-
cantly higher doses of radiation (up to 100Gy and
more). The synergistic behavior of hyperthermia
and radiation is a well-known phenomenon so
interstitial heating techniques also have been de-
veloped for the treatment of prostatic tumors.
Besides radio-frequency (RF-), microwave and
ultrasound applicators, self-regulating thermoseeds
have been used [11,12], which are heated by an
externally applied AC magnetic "eld (25}50kHz,
2 kA/m). The special feature of self-regulating ther-
moseeds arises from the ferromagnetic alloy, which
changes from the ferromagnetic to the nonmagnetic
state at the so-called Curie point (¹

, typically at
553C), which also indicates the temperature, at
which eddy current heating decreases drastically.
As with other interstitial heating methods, heat
sources must be implanted in an array, where each
of the antennas or seeds must have a spacing of
around 1 cm to the adjacent source in order to
obtain a more or less homogeneous temperature
pattern throughout the tumor. Since all seeds have
to be implanted exactly perpendicular to the
H

"eld main axis, a limiting factor is the migration
of the seeds, which causes a decrease of the speci"c
power absorption (SAR) and in these cases thermal
underdosage [13]. In most of the studies toxicity
was acceptable (grade I/II). In our ongoing phase II
study for locally advanced prostate carcinomas,
interstitial thermoseed hyperthermia plus conform-
al radiotherapy has indicated good tolerability so
far and no acute complications after thermoseed
hyperthermia. Since July 1997 more than 50 pa-
tients have been treated. Intraprostatic temper-
atures were within the e!ective range, i.e., between
423C and 463C, whereas in the urethra 383C}433C
were measured. The PSA values decreased from
11.6ng/ml (initial) to 0.30 ng/ml within 1 year after
therapy.
2. Magnetic 6uid hyperthermia (MFH): rationale
and perspectives
MFH is a completely new approach for deep-
tissue hyperthermia application because it couples
the energy magnetically to nanoparticles in the
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target region, so that bone or boundaries of di!er-
ent conductive tissues do not interfere with power
absorption as with E-"eld dominant systems used
for e.g., regional hyperthermia [14,15]. A further
potential arises with magnetic nanoparticles we
generated for certain types of cancer, e.g., glioblas-
toma and prostate carcinoma cells, which are taken
up selectively by malignant cells but not by normal
cells of the same tissue type.
As it is typical for interstitial antennas or other
&hot sources' like thermoseeds, the tissue is exclus-
ively heated by thermal conduction. Therefore the
temperature homogeneity and the minimum tumor
temperature depend strongly on the spacing of
heating elements (typically)1 cm). Taking both
together, biological selectivity and a much larger
number (lower spacing) of heating elements (coated
nanoscaled particles) of a magnetic #uid, one
should expect theoretical advantages of biological
heat targeting and temperature homogeneity by the
MFH, which were missing in the conventional
techniques used so far.
Di!erential endocytosis of modi"ed aminosilan
magnetite nanoparticles into primary glioblastoma
cells but not in normal glial cells in vitro, has been
reported previously [16]. In this study, we observed
a 10-fold higher uptake by glioblastoma cells than
by normal cells.
Further new aminosilan-type nanoparticle prep-
arations have been manufactured at the Institute of
New Materials (INM) Saarbruecken (Germany),
which are taken up by prostate carcinoma cells but
not by normal prostate cells, endothelial cells or
"broblasts in vitro. Preliminary data indicate that
the malignant cells take up nine times more par-
ticles than normal cells do. A sample micrograph is
shown in Fig. 1, where a "broblast (F) and a pros-
tate carcinoma cell (ProstCA) are adhering close to
each other. The malignant cell exhibits a clearly
visible pigmentation due to large nanoparticle
uptake in contrast to the adjacent "broblast.
Identi"cation of cell type was performed by
immuncytological analysis. Since the prostate car-
cinoma culture contained 100% cytokeratin 18
and cytokeratin 8 cells, no normal prostate cells
were present in the culture. The culture was in the
5th passage and thawed from frozen stock, so the
presence of any macrophages was very unlikely.
Fibroblast marker positive cells were clearly dis-
cernible by their morphology typical of the "bro-
blasts in contrast to the epithelial-type cells of
prostate carcinoma.
Since uptake of these particles is also observed
into macrophages in vivo (data not shown), a sys-
temic targeting approach is not promising.
Methods of the so-called interventional radiology
are required to precisely in"ltrate the tumor. In the
case of brain tumors, conventional stereotactic and
navigation systems o!er an accurate positioning.
Application of MFH to prostate carcinomas re-
quires ferro#uid administration under sonographic
control.
3. AC magnetic 5eld application: the new clinical
MFH therapy system
Besides biocompatible magnetic nanoparticles
stabilized as a magnetic #uid, MFH requires also
an AC magnetic "eld applicator system. Note that
physical dimensions and "eld-frequency para-
meters must match the limitations given by eddy
current heating of the highly conductive tissue as it
was calculated earlier [15]. The technical and
medical requirements of such an applicator system
in terms of e.g., "eld homogeneity, accuracy of "eld
strength and frequency, safety, choice of treatment
volume, thermometry and clinical quality assur-
ance have been largely underestimated so far. In
experimental setups to treat small animals, the con-
struction of an AC magnetic "eld applicator is
relatively simple. Both, induction coils and fer-
romagnetic core-coil constructions can be used as
applicators because currents and voltage are mod-
erate and controllable using resonance circuits. In
contrast, in a clinical situation a much larger air
volume (at least 5}10 000 cm for regional hyper-
thermia) has to be &"lled up' with the AC magnetic
"eld, which is a very power consuming approach.
On the other hand, large currents and voltages
e!ect electrical and operating safety of the overall
system. Field homogeneity is crucial, because each
particle has its speci"c power absorption, which is
only constant if the applied "eld is almost homo-
geneous. Field gradients yield thermal gradients
even when a homogeneous particle distribution has
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Fig. 1. Phase-contrast light microscopic picture of a prostate carcinoma cell and a "broblast cell lying adjacent to each other. Whereas
the tumor cell shows remarkable pigmentation due to large nanoparticle uptake, the adjacent "broblast cell depicts lower pigmentation,
i.e., no or lower particle uptake. The cell types were determined in separate experiments according to their morphology in combination
with immunocytological data.
been achieved. Since it is more di$cult to achieve
a homogeneous particle distribution within the tis-
sue than in a homogeneous "eld in air, the "eld
should be as homogeneous as possible. Further-
more, heating of a small amount of nanoparticles
(about 10mg ferrite/g tumor) requires about
5 times higher "eld amplitudes (in the order of
10 kA/m) in comparison to thermoseed heating.
For these overall requirements and limitations, in-
ductive coils are not suitable in contrast to ther-
moseed hyperthermia. Scaling up such a system to
the MFH requirements would be necessarily asso-
ciated with unacceptable high E-"elds, power and
heat losses close to the patient and high operating
costs. Therefore, a ferrite-core-based applicator sys-
tem is the only alternative, which can be used for
medical MFH application.
By the end of 2000, the "rst prototype of a clini-
cal MFH therapy system will be set up at the
ChariteH Medical School, Campus Virchow-
Klinikum, Clinic of Radiation Oncology in Berlin.
It is a ferrite-core applicator operating at a fre-
quency of 100 kHz with an adjustable vertical aper-
ture of 30}45 cm. The "eld strength is adjustable
from 0 to 15 kA/m. A sketch of the new system
is shown in Fig. 2. The system generates a "eld,
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Fig. 2. Sketch of the "rst prototype MFH therapy system (MFH Hyperthermiesysteme GmbH, Berlin, Germany). The AC magnetic
"eld axis is perpendicular to the axial direction of the patient couch (1). The therapy system is for universal application, i.e., suitable for
MFH within, in principle, any body region. It is a ferrite-core applicator (2) operating at a frequency of 100 kHz with an adjustable
vertical aperture of 30}50 cm (3). The "eld strength is adjustable from 0 to 15 kA/m. The system is air cooled (4). Aperture, "eld strength,
thermometry and further system parameters are on-line monitored and adjusted manually by the physician at the control unit (5). The
temperature is measured invasively with #uorooptic temperature probes within the tumor and at reference points outside the patient (6).

Fig. 3. 3D "eld strength distributions were calculated using the &"nite-di!erence-time-domain-(FDTD)-method' for di!erent applicator
apertures, currents, geometry of the core and axial positions of the patient. One example of the visualized results is shown in Fig. 3A (3D
vector diagram, coronary view, 24 cm aperture, 15 kA/m) and 3B (corresponding numerical plot).
perpendicular to the axial direction of the patient
couch. The core of the system is air cooled and
connected to a heat exchanger located in the ceil-
ing.
The treatment room is shielded and several sur-
veillance systems are implemented for the safety of
the physician and the patient. In the foreground,
the physician is shown at the terminal, where he
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controls the temperature elevations, the magnetic
"eld strength and the surveillance systems. Video
cameras are installed for the communication be-
tween patient and physician during the therapy
course. For all variations of aperture, currents, ge-
ometry of the core and axial positions of the pa-
tient, the resulting 3D "eld strength distributions
were calculated using the &"nite-di!erence-time-do-
main-(FDTD)-method'. One example of the visual-
ized results is shown in Fig. 3A (3D vector diagram)
and 3B (numerical plot). The MFH therapy system
has been developed for universal application, espe-
cially for regional hyperthermia. With this equip-
ment, brain tumors as well as prostate and other
cancer entities can be treated very homogeneously
with the required AC magnetic "eld. The system is
equipped with a #uorooptic thermometry with
0.55mm diameter single channel probes or 0.9mm
multi-channel probes (typically four-fold probes
with 0.5 cm spacing) for thermal mapping, so that
during AC magnetic "eld application the temper-
ature can be measured on-line in the target region
and at free eligible reference points. The temperature
course and further data like power and setup para-
meters are displayed on a personal computer during
therapy. System control and thermometry have been
implemented in a new application software. The AC
magnetic "eld strength is manually adjusted to the
desired steady-state temperature in the tumor, i.e.,
the average temperature of at least three target
measurement points. The thermometry device is
further equipped with a calibration setup unit. The
accuracy of the thermoprobes is$0.33C, which is
necessary for hyperthermia application in general.
4. Phase I/ II clinical concept for brain tumors
Candidates for MFH brain tumor application
are circumscribed glioblastomas, brain metastases,
residual disease after glioblastoma resection and
recurrent brain tumors. Application to the brain
implies moderate thermal dosage, i.e., &classical hy-
perthermia' at temperatures of 423C}453C, because
treatment volumes are larger than in the case of
thermal ablation techniques (e.g., laser-induced
thermal therapy). Thermal dose escalation is op-
tional depending on toxicity and tolerance of the
"rstMFH therapies. Analogous to other interstitial
hyperthermia applications, MFH of brain tumors
will be generally performed without anesthesia,
because (1) it may interfere with perfusion and
metabolic status of the treated tissue and (2) the
requirements that the patient is able to communic-
ate any pain or discomfort to the physician during
treatment. The experience with conventional re-
gional hyperthermia systems has shown so far that
this is an important aid to avoid normal tissue
damage. In response to the patient's sensations, the
physician can reduce the "eld power. However,
since it is known that thermal dose parameters are
clearly correlated with therapeutic outcome, this
reduction might also increase the risk of thera-
peutic failure. Analogous to thermoseed interstitial
hyperthermia, patients who have metallic non-re-
movable compounds (e.g., prosthesis, fragments,
cardiac pacemaker, arti"cial hearts) within or near
the treatment region must be excluded from the
study.
The following strategies are intended with brain
tumors: MFH of non-resectable metastasis or lim-
ited sized ()3 cm) glioblastomas will be treated by
stereotactic implantation of ferro#uid (15mg Fe/g
tumor), 5}6x MFH (453C, 30min) plus conformal
external beam radiotherapy (52Gy, total 60Gy
plus dose escalation). MFH of residual disease after
glioblastoma resection will be done intraoperative-
ly, i.e., as an open biopsy approach: multifocal
implantation of ferro#uid into the 1}2 cmmargin of
the resection hole, 5}6 MFH treatments (453C,
30min) in combination with conformal external
beam radiotherapy (EBRT: 52Gy, total 60Gy
plus dose escalation). 30}45min after ferro#uid ap-
plication, the AC magnetic "eld is applied. Hyper-
thermia treatment is repeated twice a week. A #ow
chart of this concept is shown in Fig. 4.
The physician prescribes the desired steady-state
temperature by regulating the applied "eld
strength. Before each MFH therapy, CT and MRI
are used to verify the appropriate distribution of
the ferro#uid load. Positron-emission-tomography
(PET) is also used routinely at our clinic so that the
identi"cation of metabolically active, e.g., residual,
tumor tissue can be localized for subsequent ferro-
#uid applications. Analogous to the results of
earlier animal experiments, we expect that the
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Fig. 4. Concept of a phase I/II study for the treatment of
brain tumors with MFH in combination with conventional
radiotherapy (Tm: estimated tumor mass).
&thermal bystander e!ect' [17] increases step-by-
step the homogeneity of the intratumoral nanopar-
ticle distribution and therefore heat deposition
throughout the tumor. The heat driven extension of
the particle distribution into the critical tumor
margin is a desired e!ect.
5. MFH for locally advanced prostate carcinomas
+ a perspective
The use of interstitial MFH at temperatures of
433C}473C in thermoradiotherapy of locally ad-
vanced carcinoma of the prostate seems very prom-
ising. As described above, improvements in thermal
homogeneity observed with MFH are expected to
overcome limitations of treatment e$cacy due to
&cold spots' within the target volume, which can be
encountered using interstitial seeds. A current
study con"rmed a constant temperature within the
prostate [18]. In a clinical setting, transperineal
implantation of ferro#uid depots in the prostate
can be done under transrectal ultrasound guidance,
similar to the technique currently used for ther-
moseed placement.
Animal experiments with Dunning prostate car-
cinoma of the rat are in progress to further evaluate
the e!ects of MFH and to establish the optimal
treatment temperature. A clinical concept of se-
quential MFH as an adjunct to conformal external
beam radiation therapy will be formulated soon.
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